Small-Cap Biotech Stocks
Smaller biotechnology companies worth $300 million to $2 billion with enough trading volume to buy and sell easily.
Stocks matching the screen
Data as of the October 29, 2026 close| VIRVir Biotechnology, Inc. | Vir Biotechnology, Inc. | 11.75 | Strong Buy 4.67 | 9 | 21.00 | +78.7% | Nov 4, 2026 |
| TRVITrevi Therapeutics, Inc. | Trevi Therapeutics, Inc. | 13.81 | Strong Buy 4.82 | 11 | 28.18 | +104% | Nov 12, 2026 |
| BRVEBraveheart Bio, Inc. | Braveheart Bio, Inc. | 21.19 | Strong Buy 5.00 | 5 | 45.25 | +114% | Dec 8, 2026 |
| ADRXADARx Pharmaceuticals, Inc. | ADARx Pharmaceuticals, Inc. | 17.85 | — | — | — | — | — |
| COAGHemab Therapeutics Holdings, Inc. | Hemab Therapeutics Holdings, Inc. | 40.42 | Strong Buy 4.83 | 6 | 62.67 | +55.0% | Nov 10, 2026 |
| MLYSMineralys Therapeutics, Inc. | Mineralys Therapeutics, Inc. | 21.24 | Strong Buy 4.64 | 11 | 46.33 | +118% | Nov 9, 2026 |
| ZBIOZenas BioPharma, Inc. | Zenas BioPharma, Inc. | 28.76 | Strong Buy 4.75 | 8 | 47.88 | +66.5% | — |
| NTLAIntellia Therapeutics, Inc. | Intellia Therapeutics, Inc. | 13.23 | Buy 3.65 | 20 | 23.11 | +74.7% | Nov 5, 2026 |
| MAZEMaze Therapeutics, Inc. | Maze Therapeutics, Inc. | 31.93 | Strong Buy 4.92 | 13 | 61.50 | +92.6% | Nov 5, 2026 |
| QUREuniQure N.V. | uniQure N.V. | 25.30 | Strong Buy 4.62 | 13 | 61.43 | +143% | Nov 9, 2026 |
| KLRAKailera Therapeutics, Inc. | Kailera Therapeutics, Inc. | 13.41 | Strong Buy 4.83 | 6 | 42.75 | +219% | Nov 11, 2026 |
| STOKStoke Therapeutics, Inc. | Stoke Therapeutics, Inc. | 26.35 | Strong Buy 4.86 | 14 | 46.46 | +76.3% | — |
| NUVBNuvation Bio Inc. | Nuvation Bio Inc. | 4.77 | Strong Buy 4.62 | 13 | 13.00 | +172% | Nov 2, 2026 |
| NVAXNovavax, Inc. | Novavax, Inc. | 10.47 | Buy 3.67 | 9 | 14.22 | +35.8% | Nov 5, 2026 |
| RAREUltragenyx Pharmaceutical Inc. | Ultragenyx Pharmaceutical Inc. | 16.78 | Buy 3.86 | 21 | 26.25 | +56.4% | Nov 3, 2026 |
| REPLReplimune Group, Inc. | Replimune Group, Inc. | 17.39 | Buy 4.25 | 8 | 19.50 | +12.1% | — |
| URGNUroGen Pharma Ltd. | UroGen Pharma Ltd. | 33.48 | Strong Buy 4.63 | 8 | 60.00 | +79.2% | Nov 5, 2026 |
| TRAXFirst Tracks Biotherapeutics | First Tracks Biotherapeutics | 45.23 | Strong Buy 4.75 | 12 | 74.17 | +64.0% | Nov 11, 2026 |
| IMCRImmunocore Holdings plc | Immunocore Holdings plc | 31.27 | Buy 4.23 | 13 | 62.73 | +101% | Nov 5, 2026 |
| OCULOcular Therapeutix, Inc. | Ocular Therapeutix, Inc. | 7.31 | Strong Buy 4.67 | 12 | 26.00 | +256% | Nov 3, 2026 |
| GPCRStructure Therapeutics Inc. | Structure Therapeutics Inc. | 21.94 | Strong Buy 4.63 | 16 | 105.78 | +382% | Nov 5, 2026 |
| INVAInnoviva, Inc. | Innoviva, Inc. | 21.31 | Buy 4.20 | 5 | 35.00 | +64.2% | Nov 4, 2026 |
| TYRATyra Biosciences, Inc. | Tyra Biosciences, Inc. | 21.48 | Strong Buy 4.73 | 15 | 47.45 | +121% | Nov 4, 2026 |
| ANABAnaptysBio, Inc. | AnaptysBio, Inc. | 48.64 | Strong Buy 4.63 | 8 | 87.25 | +79.4% | Nov 3, 2026 |
| TSHATaysha Gene Therapies, Inc. | Taysha Gene Therapies, Inc. | 4.22 | Strong Buy 4.77 | 13 | 13.00 | +208% | Nov 3, 2026 |
| DMRADamora Therapeutics, Inc. | Damora Therapeutics, Inc. | 22.01 | Strong Buy 4.90 | 10 | 46.89 | +113% | Nov 5, 2026 |
| OMEROmeros Corporation | Omeros Corporation | 18.95 | Buy 4.33 | 3 | 27.50 | +45.1% | Nov 12, 2026 |
| KARDKardigan, Inc. | Kardigan, Inc. | 14.31 | Strong Buy 4.80 | 5 | 38.67 | +170% | Nov 10, 2026 |
| NKTRNektar Therapeutics | Nektar Therapeutics | 39.18 | Buy 4.40 | 15 | 133.08 | +240% | Nov 5, 2026 |
| LBRXLB Pharmaceuticals Inc | LB Pharmaceuticals Inc | 40.15 | Strong Buy 4.64 | 11 | 58.00 | +44.5% | Nov 5, 2026 |
| SNDXSyndax Pharmaceuticals, Inc. | Syndax Pharmaceuticals, Inc. | 14.15 | Strong Buy 4.83 | 12 | 37.27 | +163% | Nov 2, 2026 |
| VORVor Biopharma Inc. | Vor Biopharma Inc. | 20.91 | Strong Buy 4.67 | 9 | 41.20 | +97.0% | Nov 12, 2026 |
| SLNSilence Therapeutics plc | Silence Therapeutics plc | 19.80 | Buy 4.29 | 7 | 33.00 | +66.7% | Nov 5, 2026 |
| DRTSAlpha Tau Medical Ltd. | Alpha Tau Medical Ltd. | 13.23 | Buy 4.40 | 5 | 17.80 | +34.5% | Nov 19, 2026 |
| RAPPRapport Therapeutics, Inc. | Rapport Therapeutics, Inc. | 24.21 | Strong Buy 4.94 | 16 | 62.71 | +159% | Nov 5, 2026 |
| MNKDMannKind Corporation | MannKind Corporation | 3.50 | Strong Buy 4.75 | 8 | 7.84 | +124% | Nov 4, 2026 |
| IMTXImmatics N.V. | Immatics N.V. | 7.31 | Strong Buy 5.00 | 9 | 16.97 | +132% | Nov 16, 2026 |
| JANXJanux Therapeutics, Inc. | Janux Therapeutics, Inc. | 17.83 | Strong Buy 4.61 | 18 | 36.24 | +103% | Nov 5, 2026 |
| INBXInhibrx, Inc. | Inhibrx, Inc. | 73.65 | Strong Buy 4.50 | 4 | 266.67 | +262% | Nov 13, 2026 |
| MLTXMoonLake Immunotherapeutics | MoonLake Immunotherapeutics | 12.57 | Buy 4.13 | 15 | 28.54 | +127% | Nov 4, 2026 |
| LTGOLatigo Biotherapeutics, Inc. | Latigo Biotherapeutics, Inc. | 15.54 | Strong Buy 5.00 | 4 | 52.25 | +236% | Dec 3, 2026 |
| SVRASavara Inc. | Savara Inc. | 4.95 | Strong Buy 4.67 | 9 | 11.06 | +123% | Nov 11, 2026 |
| PRMEPrime Medicine, Inc. | Prime Medicine, Inc. | 5.24 | Strong Buy 4.50 | 14 | 7.11 | +35.8% | Nov 6, 2026 |
| CGEMCullinan Oncology, Inc. | Cullinan Oncology, Inc. | 15.45 | Strong Buy 4.92 | 12 | 33.45 | +116% | Nov 5, 2026 |
| KURAKura Oncology, Inc. | Kura Oncology, Inc. | 10.56 | Strong Buy 4.69 | 16 | 31.85 | +202% | Nov 3, 2026 |
| AKTSAkoustis Technologies, Inc. | Akoustis Technologies, Inc. | 16.85 | Strong Buy 4.90 | 10 | 35.88 | +113% | Nov 12, 2026 |
| MGTXMeiraGTx Holdings plc | MeiraGTx Holdings plc | 9.71 | Strong Buy 4.50 | 8 | 27.75 | +186% | Nov 12, 2026 |
| ORICORIC Pharmaceuticals, Inc. | ORIC Pharmaceuticals, Inc. | 8.99 | Strong Buy 4.75 | 16 | 21.64 | +141% | Nov 12, 2026 |
| GLUEMonte Rosa Therapeutics, Inc. | Monte Rosa Therapeutics, Inc. | 10.87 | Strong Buy 4.80 | 10 | 26.88 | +147% | Nov 5, 2026 |
| ANROAlto Neuroscience, Inc. | Alto Neuroscience, Inc. | 23.47 | Strong Buy 4.82 | 11 | 38.38 | +63.5% | Nov 11, 2026 |
End-of-day prices and company fundamentals from EODHD. Fundamentals are refreshed after each earnings report. Ratios that are negative or not meaningful are shown as —. For information only, not investment advice.
Screening criteria
- Industry: Biotechnology
- Market cap between $300 million and $2 billion
- Average daily volume of 300,000 shares or more over 3 months
Common stocks and ADRs on the NYSE, Nasdaq and NYSE American; ETFs, OTC stocks and halted stocks excluded. Change or add filters above to refine the list; the full stock screener has more than 60 filters.
About this screen
Small-cap biotechs are often clinical-stage companies whose value rests on one or a few drug candidates still in trials. A single data readout, regulatory decision or partnership can move the share price dramatically in either direction. Most have little or no revenue and fund research by raising money, so share dilution is common. This list covers companies worth $300 million to $2 billion.
A minimum of 300,000 shares in average daily volume removes thinly traded names where spreads are wide. The Analysts tab shows ratings, price targets and the next earnings date. Short interest matters for event risk, so add the short % of float filter or check it in the Filters tab. Cash runway and trial timelines are in company filings, not in this table.
Small-Cap Biotech Stocks FAQ
Which small-cap biotech stocks are the largest?
As of the October 29, 2026 close, 124 biotechnology stocks with a market cap between $300 million and $2 billion traded 300,000 or more shares a day on average. The largest companies on the list are Vir Biotechnology, Inc. (VIR), Trevi Therapeutics, Inc. (TRVI) and Braveheart Bio, Inc. (BRVE).
What is a clinical-stage biotech company?
It is a company testing drug candidates in human trials but without an approved product on the market. Revenue, if any, usually comes from partnerships or grants, and losses are funded by cash raised from investors.
What is cash runway?
Cash runway is how long a company can fund operations with the cash it has, based on its recent spending. Biotechs with short runways often need to raise money soon, which can dilute existing shareholders.
Other stock screens
Sectors & industries
- Best Semiconductor Stocks
- Semiconductor Equipment Stocks
- Best REITs
- High-Yield REITs
- Residential REITs
- Industrial and Logistics REITs
- Data Center and Tower REITs
- Healthcare REITs
- Retail REITs
- Office REITs
- Mortgage REITs
- Best Bank Stocks
- Regional Bank Stocks
- Insurance Stocks
- Best AI Stocks
- Best Software Stocks
- Cybersecurity Stocks
- Cloud Computing Stocks
- Best Biotech Stocks
- Pharmaceutical Stocks
- Medical Device Stocks
- Best Energy Stocks
- Oil and Gas Stocks
- Pipeline and Midstream Stocks
- Best Utility Stocks
- Nuclear and Uranium Stocks
- Solar Stocks
- Defense Stocks
- Airline Stocks
- Electric Vehicle Stocks
- Gold Mining Stocks
- Copper and Metals Mining Stocks
- Steel Stocks
- Consumer Staples Stocks
- Restaurant Stocks
- Homebuilder Stocks
- Railroad and Trucking Stocks
- Telecom Stocks
- Chinese Stocks Listed in the US
Dividend & income stocks
- Dividend Stocks
- High Dividend Yield Stocks
- Dividend Growth Stocks
- Dividend Aristocrats
- Dividend Kings
- Monthly Dividend Stocks
- Safe Dividend Stocks
- Fast Dividend Growth Stocks
- Blue-Chip Dividend Stocks
- Dividend Stocks for Retirement
- High Dividend Stocks Under $10
- Upcoming Ex-Dividend Stocks
- High Yield, Low Payout Stocks
- High Free Cash Flow Dividend Stocks
- Dividend Stocks Near 52-Week Lows
Value, quality & size
- Value Stocks
- Growth Stocks
- Penny Stocks
- Undervalued Stocks
- Low P/E Stocks
- Stocks Trading Below Book Value
- GARP Stocks
- High Free Cash Flow Yield Stocks
- Low EV/EBITDA Stocks
- High ROE Stocks
- Quality Stocks
- High Profit Margin Stocks
- Debt-Free Stocks
- Fastest-Growing Companies
- Rule of 40 Stocks
- High EPS Growth Stocks
- Mega-Cap Stocks
- Large-Cap Stocks
- Mid-Cap Stocks
- Best Small-Cap Stocks
- Micro-Cap Stocks
- Stocks Under $10
- Low Beta Stocks
- High Beta Stocks
- Recent IPOs
Momentum & technicals
- Stocks at 52-Week Highs
- Stocks at 52-Week Lows
- Oversold Stocks
- Overbought Stocks
- Most Shorted Stocks
- Golden Cross Stocks
- Momentum Stocks
- Best-Performing Stocks of 2026
- Worst-Performing Stocks This Year
- Death Cross Stocks
- Stocks Above the 200-Day Moving Average
- Stocks Below the 200-Day Moving Average
- Unusual Volume Stocks
- Beaten-Down Quality Stocks
- Multibagger Stocks
- Short Squeeze Candidates